JP2012523416A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523416A5
JP2012523416A5 JP2012504759A JP2012504759A JP2012523416A5 JP 2012523416 A5 JP2012523416 A5 JP 2012523416A5 JP 2012504759 A JP2012504759 A JP 2012504759A JP 2012504759 A JP2012504759 A JP 2012504759A JP 2012523416 A5 JP2012523416 A5 JP 2012523416A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
methyl
isobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012504759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030038 external-priority patent/WO2010117979A2/en
Publication of JP2012523416A publication Critical patent/JP2012523416A/ja
Publication of JP2012523416A5 publication Critical patent/JP2012523416A5/ja
Pending legal-status Critical Current

Links

JP2012504759A 2009-04-09 2010-04-06 セロトニンおよびノルエピネフリン再取り込み阻害剤 Pending JP2012523416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16807909P 2009-04-09 2009-04-09
US61/168,079 2009-04-09
PCT/US2010/030038 WO2010117979A2 (en) 2009-04-09 2010-04-06 Serotonin and norepinephrine reuptake inhibitor

Publications (2)

Publication Number Publication Date
JP2012523416A JP2012523416A (ja) 2012-10-04
JP2012523416A5 true JP2012523416A5 (enExample) 2013-05-09

Family

ID=42698378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504759A Pending JP2012523416A (ja) 2009-04-09 2010-04-06 セロトニンおよびノルエピネフリン再取り込み阻害剤

Country Status (14)

Country Link
US (1) US8173821B2 (enExample)
EP (1) EP2417124B1 (enExample)
JP (1) JP2012523416A (enExample)
KR (1) KR101378260B1 (enExample)
CN (1) CN102388036A (enExample)
AR (1) AR075988A1 (enExample)
AU (1) AU2010234610B2 (enExample)
BR (1) BRPI1014382A2 (enExample)
CA (1) CA2758251C (enExample)
EA (1) EA201171230A1 (enExample)
ES (1) ES2446644T3 (enExample)
MX (1) MX2011010658A (enExample)
TW (1) TW201103908A (enExample)
WO (1) WO2010117979A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
US7994209B2 (en) * 2009-07-13 2011-08-09 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
JP5714580B2 (ja) * 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 3−フェノキシメチルピロリジン化合物
ES2533434T3 (es) 2010-10-11 2015-04-10 Theravance Biopharma R&D Ip, Llc Inhibidores de la captación de la serotonina
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
DE69717148T2 (de) * 1996-12-10 2003-10-02 Abbott Laboratories, Abbott Park 3-pyridylenantiomere und ihre verwendung als analgetika
ES2221234T3 (es) 1997-12-19 2004-12-16 Abbott Laboratories Compuestos de eter y tioeter heterociclicos utilizados en la regulacion de la transmision sinaptica quimica.
EP1212319A2 (en) 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
WO2008023258A1 (en) * 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
BRPI0719941A2 (pt) 2006-12-06 2014-04-22 Smithkline Beecham Corp Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina

Similar Documents

Publication Publication Date Title
JP2010501534A5 (enExample)
JP2013530958A5 (enExample)
JP2014506907A5 (enExample)
JP2013032389A5 (enExample)
JP2012507535A5 (enExample)
JP2009502743A5 (enExample)
JP2013537203A5 (enExample)
JP2007302683A5 (enExample)
JP2009545527A5 (enExample)
JP2012092103A5 (enExample)
JP2014515013A5 (enExample)
JP2013525444A5 (enExample)
JP2012255026A5 (enExample)
JP2010513478A5 (enExample)
JP2013518107A5 (enExample)
JP2014507446A5 (enExample)
JP2017537066A5 (enExample)
JP2011518833A5 (enExample)
JP2014511891A5 (enExample)
JP2014507455A5 (enExample)
JP2015512931A5 (enExample)
JP2010523692A5 (enExample)
JP2010526777A5 (enExample)
JP2007529527A5 (enExample)
JP2020097577A5 (enExample)